Alida Biosciences Secures Funding and Launches Innovative Epitranscriptomic Research Tools
Summary
Alida Biosciences, a leading company in epigenomic research, has announced the successful completion of a Series A funding round, raising $7.5 million. Unlike traditional methods that can only detect one type of modification per assay, the EpiPlex kit uses non-antibody binders (NABs) that offer high affinity and minimal off-target binding. This results in superior reproducibility and accuracy, even with low amounts of RNA.Accompanying the EpiPlex kit is the EpiScout Analysis Suite, a bioinformatics platform that simplifies the interpretation of complex epitranscriptomic data. The high sensitivity and efficiency of the kit ensure high-quality results from even the smallest RNA samples, making it an invaluable tool for researchers in the field.The successful Series A funding demonstrates investor confidence in Alida Biosciences and their innovative approach to epitranscriptomics. Alida Biosciences EpiPlex kit addresses this by offering high reproducibility and accuracy, but ongoing efforts are required to establish consistent practices and benchmarks.2.